Medication-related osteonecrosis of the jaws and quality of life: review and structured analysis.

[1]  M. Schiødt,et al.  Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. , 2019, Oral surgery, oral medicine, oral pathology and oral radiology.

[2]  H. Kurita,et al.  Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review , 2018, Clinical Oral Investigations.

[3]  M. Cicciu',et al.  Oral-Health-Related Quality of Life After Surgical Treatment of Osteonecrosis of the Jaws , 2017, The Journal of craniofacial surgery.

[4]  H. Hussein,et al.  Interventions for managing medication-related osteonecrosis of the jaw. , 2017, The Cochrane database of systematic reviews.

[5]  A. Mannocci,et al.  Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: a pilot study. , 2017, La Clinica terapeutica.

[6]  S. Rogers,et al.  Quality of life considerations in head and neck cancer: United Kingdom National Multidisciplinary Guidelines , 2016, The Journal of Laryngology & Otology.

[7]  T. Dodson.  The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors. , 2015, Oral and maxillofacial surgery clinics of North America.

[8]  S. Rogers,et al.  United Kingdom nationwide study of avascular necrosis of the jaws including bisphosphonate-related necrosis. , 2015, The British journal of oral & maxillofacial surgery.

[9]  T. Dodson,et al.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[10]  Z. Sadiq,et al.  Non-complex reconstructive techniques in the management of BRONJ: a case series of patient-related outcomes , 2014, Oral and Maxillofacial Surgery.

[11]  D. Cameron,et al.  Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Constantinidis,et al.  Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires. , 2012, Anticancer research.

[13]  R. Moon,et al.  What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. , 2012, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[14]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[15]  G. Trifirò,et al.  Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient’s Quality of Life: A Single-Center, 10-Year Experience from Southern Italy , 2017, Drug Safety.

[16]  G. Gazelle,et al.  Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. , 2011, The oncologist.